资讯内容 Content

[CIT2011]支架内血栓的处理——Ron Waksman教授现场专访
Management of In-Stent Restenosis——Live Interview with Dr. Ron Waksman
作者:RonWaksman 编辑:国际循环网 时间:2011/3/22 15:40:03    加入收藏
 标签:专家访谈(专题)  关键字:支架内再狭窄 Ron Waksman 药物洗脱支架 PCI DES 

  International Circulation: The drug eluting stent was designed to attenuate the complication of in-stent restenosis but it didn’t eliminate this problem. What are the main reasons for in-stent restenosis after DES implantation?
  Dr. Waksman: Yes it is true that restenosis has been significantly reduced by the use of drug eluting stents but we still see about 5% of target lesion revascularization with simple lesions and with complex lesions we see them up to 10%. It is multi-factorial; there is not one single cause. For example, it could be mechanical as we have seen some stent fractures. When the stent fractures, the polymer also fractures and the drug is released and this, in itself, can induce restenosis, usually focal restenosis. There are some biological reasons. Sometimes the drug is not effective and that is also seen in oncology that not everyone is responsive to the drugs or there is some resistance to the drugs. We also see some inflammation from the polymer. Primarily in the first generation stents, we have seen that the polymer induces neointimal inflammation and this can lead to restenosis. We are also seeing recently very late restenosis which is basically complete healing which was initially delayed but there is a price to pay for that with very late restenosis. We have seen in some of the trials, a TLR rate of 24% up to 5 years. That is pretty high when you consider 25% restenosis rate is what we used to see after 6 months, but with the drug eluting stents we can see it at 4 or 5 years.



[1]  [2]  [3]  下一页

注册

网友评论仅供其表达个人看法,并不表明国际循环同意其观点或证实其描述。 发表评论需登陆

点击排行 Top Hits

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

国际循环 版权所有  2008-2020 icirculation.com  All Rights Reserved